Supplements vergleichen

Investigational — NO approved monotherapy dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.5 mg maintenance. There is no approved standalone regimen; do not self-dose an unapproved drug.

Any time

Einmal wöchentliche subkutane Injektion (nur in Erprobung)

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Any time

Subkutane einmal wöchentliche Injektion (Ozempic / Wegovy)

• Not a dietary supplement and not an approved standalone drug — investigational; do not self-source grey-market vials
• History of pancreatitis (amylin/incretin-class caution)
• Pregnancy and breastfeeding

• Oral medications (delayed gastric emptying)
• Insulin / insulin secretagogues (sulfonylureas)
• GLP-1 / incretin drugs (e.g. semaglutide)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists